Melanoma

IMUNON Reports Second Quarter 2023 Financial Results and Provides Business Update

Advances Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a Strong Balance Sheet Conference Call…

2 years ago

Sensus Healthcare Announces New $3 Million Share Repurchase Program

BOCA RATON, Fla., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in…

2 years ago

IO Biotech Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023

NEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer…

2 years ago

Verrica Pharmaceuticals Reports Second Quarter 2023 Financial Results

– In July, FDA approved YCANTH™ for the treatment of molluscum, a highly contagious viral skin infection affecting approximately 6…

2 years ago

IO Biotech, Inc. Announces $75 Million Private Placement Financing

Offering includes participation from both new and existing healthcare-dedicated investorsProceeds extend the company’s cash runway into the fourth quarter of…

3 years ago

Preclinical Data Showing Strong Immunogenicity and Protection with IMUNON’s PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv

LAWRENCEVILLE, N.J., Aug. 07, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral…

3 years ago

Moderna Reports Second Quarter 2023 Financial Results and Provides Business Updates

Second quarter 2023 revenues of $0.3 billion; net loss of $1.4 billion and loss per share of $3.62Company expecting 2023…

3 years ago

IMUNON to Hold Second Quarter 2023 Financial Results and Business Update Conference Call on Thursday, August 10, 2023

LAWRENCEVILLE, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated…

3 years ago

Advanced Health Intelligence to re-enter China with Exclusive License Deal with Changlin Network Technology Ltd

HighlightsAHI executes a binding exclusive, perpetual license with Shanghai-based Changlin Network Technology Ltd.Changlin is backed by founders with 50 years…

3 years ago

Marpe Technologies Receives FDA Breakthrough Device Designation for its Revolutionary Dermatology Screening System

CAESAREA, ISRAEL / ACCESSWIRE / July 31, 2023 / Marpe Technologies, a leading innovator in dermatology screening solutions, is thrilled…

3 years ago